Abstracts Archive - Page 2602 of 2607 - ACR Meeting Abstracts

Abstract Number: 14 • 2012 ACR/ARHP Annual Meeting
EPAC1 Activation Is Required for NFkB Nuclear Translocation and Osteoclast Differentiation
Aranzazu Mediero¹ and Bruce N. Cronstein², ¹Medicine, Division of Translational Medicine, NYU School of Medicine, New York, NY, ²Internal Medicine, NYU School of Medicine, Division of Rheumatology, New York, NY
Background/Purpose: Previous work demonstrated that one mechanism by which bisphosphonates inhibit osteoclast differentiation and function is via inhibition of Rap1A isoprenylation and, as a result,…
Abstract Number: 15 • 2012 ACR/ARHP Annual Meeting
Adenosine A_2A Receptor Stimulation Inhibits OC Formation by Suppressing NFkB Translocation to the Nucleus by A PKA-ERK1/2 Mediated Mechanism
Aranzazu Mediero¹ and Bruce N. Cronstein², ¹Medicine, Division of Translational Medicine, NYU School of Medicine, New York, NY, ²Internal Medicine, NYU School of Medicine, Division of Rheumatology, New York, NY
Background/Purpose: Adenosine, a nucleoside released at sites of injury and hypoxia, mediates its effects via activation of G-protein-coupled receptors (A1, A2A, A2B, A3). Previously we…
Abstract Number: 16 • 2012 ACR/ARHP Annual Meeting
Adenosine A_2A Receptor Diminishes Bone Destruction At Inflamed Sites, in Part, Via Downregulating Semaphorin4D-PlexinB1 Communication Between Osteoclasts and Osteoblasts
Aranzazu Mediero¹ and Bruce N. Cronstein², ¹Medicine, Division of Translational Medicine, NYU School of Medicine, New York, NY, ²Internal Medicine, NYU School of Medicine, Division of Rheumatology, New York, NY
Background/Purpose: Communication between osteoclasts and osteoblasts is essential for bone homeostasis. Semaphorin4D (Sema4D), expressed on the surface of and secreted by osteoclasts, macrophages and T…
Abstract Number: 17 • 2012 ACR/ARHP Annual Meeting
Synovial Overexpression of Wnt and Wnt-1-Induced Secreted Protein 1 Induces Cartilage Damage by Skewing of TGF-Beta Signaling and Reduction of the Anti-Hypertrophy Factor Sox9
Martijn H. van den Bosch¹, Arjen B. Blom¹, Peter L. van Lent², Henk M. van Beuningen¹, Fons A. van de Loo³, Esmeralda N. Blaney Davidson¹, Peter M. van der Kraan¹ and Wim B. van den Berg⁴, ¹Rheumatology Research & Advanced Therapeutics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ²Rheumatology Research & Advanced Therpeutics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ³Rheumatology Research and Advanced Therapeutics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁴Rheumatology Research and Advanced Therapeutics, Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
Background/Purpose: Although many osteoarthritis (OA) patients show significant synovial involvement, consequences are largely unknown. We found highly increased expression of canonical Wnts 2b and 16…
Abstract Number: 18 • 2012 ACR/ARHP Annual Meeting
Identification of 14-3-3å As a New Subchondral Bone Mediator Involved in Cartilage Degradation During Osteoarthritis
Sabrina Priam Jr.¹, Carole Bougault¹, Xavier Houard², Marjolaine Gosset³, Colette Salvat⁴, Francis Berenbaum⁵ and Claire Jacques¹, ¹Ur-4, Pierre et Marie Curie University Paris VI, Paris, France, ²Sorbonne Universités, UPMC Univ Paris 06, UMRS 938 and Inflammation-Immunopathology-Biotherapy Department (DHU i2B), Paris, France, ³EA 2496, Paris Descartes University, Montrouge, France, ⁴UR4, University Pierre and Marie Curie, Paris, France, ⁵Rheumatology, AP-HP, St Antoine Hospital, Paris, France
Background/Purpose: OA is a complex disease not limited to cartilage degeneration. Indeed, several experiments suggest that subchondral bone remodeling could initiate and/or contribute to cartilage…
Abstract Number: 19 • 2012 ACR/ARHP Annual Meeting
Stress-Induced Cartilage Degradation Does Not Depend On NLRP3-Inflammasome in Osteoarthritis
Carole Bougault¹, Marjolaine Gosset², Xavier Houard³, Colette Salvat⁴, Lars Godmann⁵, Thomas Pap⁵, Claire Jacques¹ and Francis Berenbaum⁶, ¹Ur-4, Pierre et Marie Curie University Paris VI, Paris, France, ²EA 2496, Paris Descartes University, Montrouge, France, ³Sorbonne Universités, UPMC Univ Paris 06, UMRS 938 and Inflammation-Immunopathology-Biotherapy Department (DHU i2B), Paris, France, ⁴UR4, University Pierre and Marie Curie, Paris, France, ⁵Institute of Experimental Muskuloskeletal Medicine, University Hospital Münster, Münster, Germany, ⁶Rheumatology, AP-HP, St Antoine Hospital, Paris, France
Background/Purpose: The cartilage matrix breakdown in osteoarthritis (OA) is due to both abnormal mechanical stress and activation of catabolic processes involving metalloproteinases (MMPs). Currently, IL-1beta…
Abstract Number: 20 • 2012 ACR/ARHP Annual Meeting
Osteoclastogenesis Is Inhibited by Immune Complexes Through Activating Fcγ Receptors
Lilyanne C. Grevers¹, Peter L.E.M. van Lent², Teun J. de Vries³, Vincent Everts³, J. Sjef Verbeek⁴ and Wim B. van den Berg⁵, ¹Rheumatology Research & Advanced Therapeutics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ²Rheumatology Research & Advanced Therpeutics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ³Oral Cell Biology, ACTA, UVA, VU University Amsterdam, Amsterdam, Netherlands, ⁴Department of Human Genetics, Leiden University Medical Center, Leiden, Netherlands, ⁵Rheumatology Research and Advanced Therapeutics, Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
Background/Purpose: Rheumatoid arthritis is characterized by chronic inflammation and osteoclast-mediated bone loss. Co-stimulatory signalling via ITAM- and ITIM-coupled receptors is essential for osteoclast formation and…
Abstract Number: 21 • 2012 ACR/ARHP Annual Meeting
IL-32 and IL-17 Interact and Aggravate Osteoclastogenesis in Rheumatoid Arthritis
Bo Young Yoon¹, Young-Mee Moon², Yang-Mi Her², Hye Jwa Oh², Jae-Seon Lee², Kyoung-Woon Kim³, Seon-Yeong Lee², Yun-Ju Woo², Kyung-Su Park², Sung-Hwan Park⁴, Ho-Youn Kim² and Mi-La Cho², ¹Inje University Ilsan Paik Hospital, Goyang, South Korea, ²Rheumatism Research Center, Catholic Research Institute of Medical Science, Catholic University of Korea, Seoul, South Korea, ³Conversant Research Consortium in Immunologic disease, The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, South Korea, ⁴Rheumatism Research Center, Catholic Research Institute of Medical Science, The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, South Korea
Background/Purpose: Interleukin (IL)-32 and IL-17 play critical roles in pro-inflammatory responses and are highly expressed in the synovium of patients with rheumatoid arthritis (RA). We…
Abstract Number: 22 • 2012 ACR/ARHP Annual Meeting
Protective Properties of Conditioned Media From Adipose Stem Cells On Osteoarthritic Chondrocytes
Maria Isabel Guillén¹, Julia Platas¹, Vicente Mirabet², Miguel Angel Castejón³, Francisco Gomar⁴ and Maria Jose Alcaraz¹, ¹Pharmacology, University of Valencia, Burjasot, Valencia, Spain, ²Generalitat Valenciana, Valencia, Spain, ³De la Ribera University Hospital, Alzira, Spain, ⁴Surgery, University of Valencia and University Hospital, Valencia, Spain
Background/Purpose: Adipose-derived mesenchymal stem cells (ASC) exhibit a high potential for cell therapy and they might also act as a cellular source for supplying soluble…
Abstract Number: 23 • 2012 ACR/ARHP Annual Meeting
Differential Effects of Bone Morphogenetic Protein 2 and 9 On Chondroprotective Transforming Growth Factor β Signaling
Arjan P. van Caam¹, Esmeralda N. Blaney Davidson¹, Elly L. Vitters², Laurie de Kroon¹, Ellen W. van Geffen³, Peter ten Dijke⁴, Wim B. van den Berg² and Peter M. van der Kraan², ¹Rheumatology Research & Advanced Therapeutics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ²Rheumatology Research and Advanced Therapeutics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ³Experimental Rheumatology, Radboud university medical center, Nijmegen, Netherlands, ⁴Department of Molecular Cell Biology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Osteoarthritis (OA) is a multifactorial disease characterized by loss of articular cartilage. TGFβ is considered as a protective factor against cartilage loss in young cartilage…
Abstract Number: 24 • 2012 ACR/ARHP Annual Meeting
The Negative Effects of Glucocorticoids On Bone Are Primarily Mediated by Genes Involved in Osteoblast Differentiation and Bone Remodelling
Katharina Blankenstein¹, Tara C. Brennan-Speranza¹, Karin Lyon¹, Colin R. Dunstan¹, Frank Buttgereit², Hong Zhou³ and Markus J. Seibel³, ¹ANZAC Research Institute, Concord, NSW, Bone Research Program, Sydney, Australia, ²Charité - Universitätsmedizin Berlin, Berlin, Germany, ³Bone Research Program, ANZAC Research Institute, The University of Sydney, Concord, Australia
Background/Purpose: Glucocorticoids are widely used as anti-inflammatory and immunosuppressive drug for the treatment of many inflammatory and auto-immune diseases. However, long-term and high-dose glucocorticoid treatment…
Abstract Number: 25 • 2012 ACR/ARHP Annual Meeting
Activation of the Canonical Wnt Signaling Pathway Is Tissue Dependent in Osteoarthritic Joints: Distinct Mechanisms of Regulation by Wnt Antagonists
Thomas Funck-Brentano¹, Wafa Bouaziz¹, Hilene Lin¹, Valerie Geoffroy¹, Eric Hay¹ and Martine Cohen-Solal², ¹INSERM U606 Paris 7 university, Paris, France, ²Rhumatologie A, INSERM U606 Hôpital Lariboisière, Centre Viggo Petersen, Paris, France
Background/Purpose: Wnt signaling pathway is a major regulator of bone and cartilage remodeling. Modulation of this pathway has lead to controversial results on joint cartilage…
• 2012 ACR/ARHP Annual Meeting
Lee C. Howley Sr. Prize for Arthritis Research Introductory Talk I
Andrew D. Luster, Massachusetts General Hospital, Charlestown, MA
Abstract Number: L10 • 2012 ACR/ARHP Annual Meeting
In Rheumatoid Arthritis Patients with Stable Low Disease Activity On Methotrexate Plus Etanercept, Continuation of Etanercept 50 Mg Weekly or 25 Mg Weekly Are Both Clinically Superior to Discontinuation: Results From a Randomized, 3-Armed, Double-Blind Clinical Trial
R.F. van Vollenhoven¹, Mikkel Østergaard², Marjatta Leirisalo-Repo³, Till Uhlig⁴, Marita Jansson⁵, Åsa Klackenberg⁵, Katherine Hutchinson⁶ and Karin Franck-Larsson⁵, ¹Clinical Trials Unit Department of Rheumatology, The Karolinska Institute, Stockholm, Sweden, ²Copenhagen University Hospital Glostrup, Copenhagen, Denmark, ³Department of Medicine, Division of Rheumatology, Helsinki University Central Hospital, Helsinki, Finland, ⁴Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁵Speciality Care Nordic Medical Affairs, Pfizer Nordic, Sollentuna, Sweden, ⁶Quanticate, Hitchin, United Kingdom
Background/Purpose: The efficacy of etanercept (ETN) in combination with methotrexate (MTX) in the treatment of rheumatoid arthritis (RA) is well established, and long-term trials1 and…
• 2012 ACR/ARHP Annual Meeting
Lee C. Howley Sr. Prize for Arthritis Research Introductory Talk II
Alisa E. Koch, Internal Medicine - Rheumatology, University of Michigan Medical School, Ann Arbor, MI

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].